カナダ - 英語 - Health Canada

pharmascience inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 150mg - risedronate sodium (risedronate sodium hemipentahydrate) 150mg - bone resorption inhibitors

カナダ - 英語 - Health Canada

pendopharm division of pharmascience inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 35mg - risedronate sodium (risedronate sodium hemipentahydrate) 35mg - bone resorption inhibitors

カナダ - 英語 - Health Canada

aa pharma inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet (delayed-release) - 35mg - risedronate sodium (risedronate sodium hemipentahydrate) 35mg - bone resorption inhibitors

カナダ - 英語 - Health Canada

modern veterinary therapeutics llc - moxidectin; imidacloprid - solution - 4mg; 40mg - moxidectin 4mg; imidacloprid 40mg - cats; mammals(miscellaneous)

カナダ - 英語 - Health Canada

modern veterinary therapeutics llc - moxidectin; imidacloprid - solution - 8mg; 80mg - moxidectin 8mg; imidacloprid 80mg - cats

カナダ - 英語 - Health Canada

modern veterinary therapeutics llc - moxidectin; imidacloprid - solution - 10mg; 40mg - moxidectin 10mg; imidacloprid 40mg - dogs

カナダ - 英語 - Health Canada

modern veterinary therapeutics llc - moxidectin; imidacloprid - solution - 25mg; 100mg - moxidectin 25mg; imidacloprid 100mg - dogs

カナダ - 英語 - Health Canada

modern veterinary therapeutics llc - moxidectin; imidacloprid - solution - 62.5mg; 250mg - moxidectin 62.5mg; imidacloprid 250mg - dogs

カナダ - 英語 - Health Canada

modern veterinary therapeutics llc - moxidectin; imidacloprid - solution - 100mg; 400mg - moxidectin 100mg; imidacloprid 400mg - dogs

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

actavis pharma, inc. - risedronate sodium hemi-pentahydrate (unii: hu2yaq274o) (risedronic acid - unii:km2z91756z), risedronate sodium monohydrate (unii: f67l43ut5c) (risedronic acid - unii:km2z91756z) - risedronate sodium anhydrous 30.1 mg - risedronate sodium is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ].  the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risedronate sodium is contraindicated in patients with the following conditions: - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see warnings and precautions (5.2) ] -